

Extraordinary Report

March 29, 2024

(TRANSLATION)

Note for readers of this English translation

On March 29, 2024, Chugai Pharmaceutical Co., Ltd. filed its Japanese-language Extraordinary Report (*Rinji Houkokusho*) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 113th Annual General Meeting of Shareholders held on March 28, 2024, pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

1. Reason for submitting the Extraordinary Report

Given that resolutions were made for the proposals at the 113th Annual General Meeting of Shareholders (the "Meeting") held on March 28, 2024, Chugai Pharmaceutical Co., Ltd. (the "Company") submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc. (the "Report").

2. Contents of the Report

(1) Date when the Meeting was held; March 28, 2024

(2) Matters for resolution

First Proposal: Appropriation of Surplus

Year-end dividend

JPY 40 per share of common stock of the Company

Second Proposal: Partial Amendment to the Articles of Incorporation

The term of office of Directors as stipulated in Article 19 of the Articles of Incorporation will be changed from two (2) years to one (1) year.

Third Proposal: Election of Nine (9) Directors

Elect Osamu Okuda, Iwaaki Taniguchi, Hitoshi Iikura, Mariko Y Momoi, Fumio Tateishi, Hideo Teramoto, Christoph Franz, James H. Sabry and Teresa A. Graham as Directors of the Company.

Fourth Proposal: Election of Two (2) Audit & Supervisory Board Members

Elect Kenichi Masuda and Mami Yunoki as Audit & Supervisory Board Members of the Company.

Fifth Proposal: Revision of Remuneration Limit of Audit & Supervisory Board Members
Revise Remuneration for Audit & Supervisory Board Members to be up to JPY180 million per year.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention" for each proposal; and Requirements for approving the proposals: Results of the resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
First Proposal	15,214,437	25,682	333	99.83%	Approved
Second Proposal	15,239,010	1,098	333	99.99%	Approved
Third Proposal					
Osamu Okuda	12,912,566	2,303,882	23,981	84.72%	Approved
Iwaaki Taniguchi	14,676,002	561,066	3,371	96.29%	Approved
Hitoshi Ikura	14,575,919	661,142	3,371	95.64%	Approved
Mariko Y Momoi	14,767,365	472,744	333	96.89%	Approved
Fumio Tateishi	14,730,599	509,508	333	96.65%	Approved
Hideo Teramoto	14,763,391	476,718	333	96.87%	Approved
Christoph Franz	14,683,305	553,763	3,371	96.34%	Approved
James H. Sabry	14,452,408	784,661	3,371	94.83%	Approved
Teresa A. Graham	14,455,911	781,158	3,371	94.85%	Approved
Fourth Proposal					
Kenichi Masuda	15,227,319	12,758	333	99.91%	Approved
Mami Yunoki	15,238,928	1,149	333	99.99%	Approved
Fifth Proposal	15,220,098	15,014	5,337	99.86%	Approved

Notes: Requirements for the approval of each proposal are as follows:

- 1) The resolution for the First Proposal the Fifth Proposal and must be adopted by the majority of the votes of the shareholders present who are entitled to exercise their voting rights.
- 2) The resolution for the Second Proposal must be adopted by the attendance of shareholders who hold majority of the voting rights of shareholders who are entitled to exercise their rights, and two-thirds (2/3) or more of votes of the shareholders present.

- 3) The resolution for the Third and the Fourth Proposals must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.
- (4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 28, 2024, was not added to the number of voting rights

Because in terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 28, 2024, as well as the votes exercised by a portion of shareholders present and confirmed by the Company at the Meeting held on March 28, 2024; and the voting rights of the shareholders present at the Meeting held on March 28, 2024, untraceable with the final decision of "for", "against" or "abstention" as to each proposal were not tallied.